These findings provide a rationale for the evaluation of IL-6 inhibitors, such as tocilizumab, and Janus kinase/signal transducer and activation of transcription (JAK/STAT) inhibitors for the treatment of ICI-associated myositis in patients with thymoma [50]. Here, IL6 is linked to thymoma.